Regeneron Pharmaceuticals, Inc. with ticker code (REGN) now have 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $1,125.00 and $700.00 calculating the mean target price we have $932.82. Now with the previous closing price of $874.37 this is indicating there is a potential upside of 6.7%. The 50 day MA is $820.63 and the 200 day moving average is $792.83. The company has a market capitalization of 96.06B. The current share price for the company is: $881.70 USD
The potential market cap would be $102,479,908,825 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.13, revenue per share of $122.63 and a 9.21% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
